Protocol Ledger

NCT07110246 · Phase II · RECRUITING

Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

Interventional Phase II clinical trial protocol NCT07110246 sponsored by UCSF in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-07 Enrollment: 96 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07110246
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)96 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07110246
Protocol FieldVerified Registry Value
NCT IdentifierNCT07110246
Consolidated Lead SponsorUCSF
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment96 participants (ESTIMATED)
Registered Start Date2025-11-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCSF Health across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI